Abivax (ABVX) said Thursday the underwriters of its American depositary share offering exercised in full their option to purchase an additional 960,000 ADSs, increasing gross proceeds to about $920 million.
The offering is expected to close Monday, subject to customary closing conditions.
Net proceeds, about $874.1 million, will be used to support the potential US commercialization of obefazimod, clinical research on ulcerative colitis and Crohn's disease, and for general corporate purposes, the company said.
Shares of Abivax were 5% higher in Thursday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments